Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Rehabilitative / geriatric care

    • Home
    • Rehabilitative / geriatric care
Company Deals

Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer’s Treatment

Fineline Cube Jul 29, 2025

China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered...

Company Deals Hospital

Shaanxi Panlong Pharmaceutical Partners with Xi’an Medical University for Multifaceted Collaboration

Fineline Cube Jan 19, 2024

Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864), a leading pharmaceutical company based in China,...

Policy / Regulatory

China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy

Fineline Cube Jan 16, 2024

The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing...

Recent updates

  • Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation
  • Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
  • Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
  • Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
  • InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.